DZ3014A1 - Médicaments pour le traitement de l'hypertension. - Google Patents

Médicaments pour le traitement de l'hypertension.

Info

Publication number
DZ3014A1
DZ3014A1 DZ000029A DZ000029A DZ3014A1 DZ 3014 A1 DZ3014 A1 DZ 3014A1 DZ 000029 A DZ000029 A DZ 000029A DZ 000029 A DZ000029 A DZ 000029A DZ 3014 A1 DZ3014 A1 DZ 3014A1
Authority
DZ
Algeria
Prior art keywords
hypertension
medicines
treatment
Prior art date
Application number
DZ000029A
Other languages
English (en)
Inventor
Martin R Wilkins
Dirk Thormahlen
Harald Waldeck
Original Assignee
Solvay Pharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharm Gmbh filed Critical Solvay Pharm Gmbh
Application granted granted Critical
Publication of DZ3014A1 publication Critical patent/DZ3014A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
DZ000029A 1999-02-16 2000-02-13 Médicaments pour le traitement de l'hypertension. DZ3014A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19906310A DE19906310A1 (de) 1999-02-16 1999-02-16 Arzneimittel zur Behandlung von Bluthochdruck

Publications (1)

Publication Number Publication Date
DZ3014A1 true DZ3014A1 (fr) 2004-03-27

Family

ID=7897580

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ000029A DZ3014A1 (fr) 1999-02-16 2000-02-13 Médicaments pour le traitement de l'hypertension.

Country Status (28)

Country Link
US (1) US6482820B2 (fr)
EP (1) EP1154777B1 (fr)
JP (1) JP2002537258A (fr)
KR (2) KR20010101922A (fr)
CN (1) CN1198619C (fr)
AR (1) AR036864A1 (fr)
AT (1) ATE295174T1 (fr)
AU (1) AU773240C (fr)
BR (1) BR0008260A (fr)
CA (1) CA2362273C (fr)
CZ (1) CZ301499B6 (fr)
DE (2) DE19906310A1 (fr)
DZ (1) DZ3014A1 (fr)
ES (1) ES2238268T3 (fr)
HK (1) HK1042247B (fr)
HU (1) HUP0105491A3 (fr)
IL (1) IL144622A (fr)
NO (1) NO329588B1 (fr)
NZ (1) NZ514058A (fr)
PL (1) PL195283B1 (fr)
PT (1) PT1154777E (fr)
RU (1) RU2270679C2 (fr)
SK (1) SK287254B6 (fr)
TR (1) TR200102386T2 (fr)
TW (1) TWI221770B (fr)
UA (1) UA63032C2 (fr)
WO (1) WO2000048601A1 (fr)
ZA (1) ZA200105828B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932555A1 (de) * 1999-07-13 2001-01-18 Solvay Pharm Gmbh Arzneimittel mit protektiver Wirkung gegen oxidativ-toxische und insbesondere gegen kardiotoxische Substanzen
CA2392076A1 (fr) * 1999-11-19 2001-05-25 Solvay Pharmaceuticals B.V. Enzymes humaines de la famille des metalloproteases
DE60129518T2 (de) * 2000-10-04 2008-03-20 Astellas Pharma Inc. Verwendung von einem Vasopressin-Antagonisten wie Conivaptan zur Herstellung eines Medikaments für die Behandlung der pulmonalen Hypertension
CA2447598A1 (fr) * 2001-05-18 2002-11-28 Solvay Pharmaceuticals Gmbh Utilisation de composes presentant une activite d'inhibition de nep/mp combinee dans la preparation de medicaments
US7126015B2 (en) * 2001-09-10 2006-10-24 Tibotec Pharmaceuticals Ltd. Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol
MXPA04006887A (es) * 2002-01-16 2004-12-06 Solvay Pharm Bv Sales solidas de compuestos de benzazepina y su uso en la preparacion de compuestos farmaceuticos.
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
WO2004062692A1 (fr) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation de substances actives a faible hydrosolubilite
US7427611B2 (en) 2003-09-26 2008-09-23 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl)-cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
US7452875B2 (en) 2003-09-26 2008-11-18 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US7262184B2 (en) 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
MXPA06005547A (es) * 2003-11-18 2006-08-17 Solvay Pharm Gmbh Composiciones farmaceuticas para el tratamiento de disfuncion, enfermedad o trastorno renal, en particular, en pacientes diabeticos.
US20050267124A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
US20050267072A1 (en) * 2004-05-14 2005-12-01 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions containing dually acting inhibitors of neutral endopeptidase for the treatment of sexual dysfunction
US20050288272A1 (en) * 2004-06-23 2005-12-29 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists
CN101080232A (zh) 2004-12-15 2007-11-28 索尔瓦药物有限公司 包含NEP－抑制剂、内源性内皮素产生系统的抑制剂和HMG CoA还原酶抑制剂的药物组合物
US20060205625A1 (en) * 2005-02-18 2006-09-14 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and diuretics
US20070292503A1 (en) * 2006-06-16 2007-12-20 Gorissen Henricus R Oral pharmaceutical composition of poorly water-soluble active substance
US20070299054A1 (en) * 2006-06-22 2007-12-27 Rajesh Jain Oral pharmaceutical composition of a poorly water-soluble active agent
JP2011511006A (ja) * 2008-01-31 2011-04-07 バンダービルト・ユニバーシティ 肺病態に対する治療

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4749688A (en) * 1986-06-20 1988-06-07 Schering Corporation Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension
EP0254032A3 (fr) * 1986-06-20 1990-09-05 Schering Corporation Inhibiteurs de la métallo-endopeptidase neutre dans le traitement de l'hypertension
CA1337400C (fr) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibiteurs de l'endopeptidase neutre
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
DE19510566A1 (de) * 1995-03-23 1996-09-26 Kali Chemie Pharma Gmbh Benzazepin-, Benzoxazepin- und Benzothiazepin-N-essigsäurederivate sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19638020A1 (de) * 1996-09-18 1998-03-19 Solvay Pharm Gmbh Die gastrointestinale Durchblutung fördernde Arzneimittel

Also Published As

Publication number Publication date
CA2362273A1 (fr) 2000-08-24
UA63032C2 (en) 2004-01-15
PL195283B1 (pl) 2007-08-31
ES2238268T3 (es) 2005-09-01
HUP0105491A2 (en) 2002-06-29
TWI221770B (en) 2004-10-11
CN1339966A (zh) 2002-03-13
TR200102386T2 (tr) 2002-01-21
CN1198619C (zh) 2005-04-27
HUP0105491A3 (en) 2002-08-28
SK10822001A3 (sk) 2002-03-05
US6482820B2 (en) 2002-11-19
PL350167A1 (en) 2002-11-18
EP1154777A1 (fr) 2001-11-21
IL144622A (en) 2006-08-20
US20020052361A1 (en) 2002-05-02
DE19906310A1 (de) 2000-08-17
KR100797665B1 (ko) 2008-01-23
NZ514058A (en) 2001-09-28
EP1154777B1 (fr) 2005-05-11
AU773240B2 (en) 2004-05-20
NO329588B1 (no) 2010-11-15
JP2002537258A (ja) 2002-11-05
PT1154777E (pt) 2005-07-29
RU2270679C2 (ru) 2006-02-27
CA2362273C (fr) 2010-05-25
HK1042247B (zh) 2005-09-23
ATE295174T1 (de) 2005-05-15
SK287254B6 (sk) 2010-04-07
CZ301499B6 (cs) 2010-03-24
NO20013958D0 (no) 2001-08-15
NO20013958L (no) 2001-10-15
AU773240C (en) 2004-11-18
CZ20012672A3 (cs) 2002-02-13
KR20010101922A (ko) 2001-11-15
HK1042247A1 (en) 2002-08-09
WO2000048601A1 (fr) 2000-08-24
DE50010284D1 (de) 2005-06-16
BR0008260A (pt) 2001-11-06
KR20070027719A (ko) 2007-03-09
ZA200105828B (en) 2002-07-15
AR036864A1 (es) 2004-10-13
AU2547600A (en) 2000-09-04

Similar Documents

Publication Publication Date Title
MA26822A1 (fr) Composes pour le traitement d'une ischemie.
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
FR15C0070I2 (fr) Composes heteroaromatiques azotes pour le traitement des maladies de cancer
MA25823A1 (fr) Compositions pour le traitement de l'eau.
MA26914A1 (fr) Derives bicycliques substitues pour le traitement d'une croissance cellulaire anormale
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
DZ1877A1 (fr) Forme posologiques d'azithromycine pour le traitement d'infection microbiennes.
FR2854074B1 (fr) Utilisation de l'ivermectine pour le traitement de desordres dermatologiques
MA25411A1 (fr) Microorganismes attenues pour le traitement d'infection.
MA25234A1 (fr) Vibromasseur pour le soulagement des maux et de la douleur.
MA26950A1 (fr) Nouveaux retinoides pour le traitement de l'emphyseme
FR13C0044I2 (fr) Utilisation de dihydroimidazolones pour le traitement de l'epilepsie canine
FR2705966B1 (fr) Compositions antimousse utiles notamment pour le traitement de troubles gastriques.
ATE259825T1 (de) Hemihydrat von 16.alpha.-bromoepiandrosterone
FR2746658B1 (fr) Valve de drainage implantable pour le traitement de l'hydrocephalie
MA25852A1 (fr) Methode pour le traitement de l'inflammation.
DZ1988A1 (fr) Thérapie de combinaison pour le traitement de l'hiv.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
MA26117A1 (fr) Nouveau compose pour le traitement de l'impuissance
FR2800614B1 (fr) Composition pour le traitement des infections des voies respiratoires
DZ1903A1 (fr) Oligonucléotides pour inhiber le role ders isoprényl protéine transférases.
ZA200110539B (en) Oxazinocarbazoles for the treatment of CNS diseases.
FR2774289B1 (fr) Medicament pour le traitement des dereglements de l'apoptose